DR-01

About Dren Bio

Dren Bio is a South San Francisco-based biotech founded in 2019, advancing a pipeline of first-in-class antibody therapeutics. The company's core approach involves engineering antibodies to selectively engage immune effector cells, like macrophages, to phagocytose and clear pathological targets. With two clinical-stage programs and a broader preclinical portfolio in oncology, immunology, and neurology, Dren aims to address significant unmet medical needs through its novel depletion mechanisms. As a private, pre-revenue company, its success hinges on clinical validation of its proprietary platforms.

Therapeutic Areas